OncoMatch/Clinical Trials/NCT06849713
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
Is NCT06849713 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Zanubrutinib and Sonrotoclax for chronic lymphocytic leukemia.
Treatment: Zanubrutinib · Sonrotoclax · Obinutuzumab — The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Exception: Prior local radiation for symptomatic disease is permitted. Short course systemic corticosteroids is permissible for disease control, improvement of performance status, or non-cancer indication (≤14 days, ≤100 mg prednisone, ≤20 mg dexamethasone, or equivalent, discontinued prior to study treatment). Inhaled, topical, and replacement/stress corticosteroids permitted. Steroid usage for autoimmune complications of CLL (e.g., ITP or AIHA) permitted.
Participants must have no prior systemic therapy for CLL or SLL, except: Prior local radiation for symptomatic disease is permitted. Short course systemic corticosteroids is permissible for disease control, improvement of performance status, or non-cancer indication. However, duration of steroid course must be ≤14 days with maximum daily dose of ≤100 mg prednisone, ≤20 mg dexamethasone, or equivalent, and must be discontinued prior to study treatment (last dose may be administered up until the morning of / prior to study treatment). Inhaled steroids, topical steroids, and replacement / stress corticosteroids are permitted independent of above rules. In cases of autoimmune complications of CLL (e.g., ITP or AIHA), steroid usage is permitted.
Cannot have received: anti-CD20 monoclonal antibody
Prior anti-CD20 monoclonal antibody therapy for any indication (malignant or non-malignant).
Lab requirements
Blood counts
absolute neutrophil count ≥1,000/µL without growth factor support (unless clearly due to disease under study); platelets ≥75,000/µL, or ≥20,000/µL if clearly due to disease under study
Kidney function
CrCl or GFR ≥30 mL/min as estimated by Cockcroft-Gault, CKD-EPI, or 24-hour urine collection
Liver function
total bilirubin ≤2 x institutional ULN, or ≤3 x institutional ULN if due to Gilbert's syndrome, or with PI approval if clearly due to disease under study; AST(SGOT)/ALT(SGPT) ≤2.5 x institutional ULN
Participants must meet the following organ and marrow function as defined below: - absolute neutrophil count ≥1,000/µL without growth factor support (filgrastim within 5 days or PEGfilgrastim within 10 days of test), unless clearly due to disease under study (per investigator) - platelets ≥75,000/µL, or ≥20,000/µL if clearly due to disease under study (per investigator) - total bilirubin ≤2 x institutional upper limit of normal (ULN), or ≤3 x institutional ULN if due to Gilbert's syndrome, or with PI approval if clearly due to disease under study - AST(SGOT)/ALT(SGPT) ≤2.5 x × institutional ULN - CrCl or GFR ≥30 mL/min as estimated by the Cockcroft-Gault equation, the CKD-EPI equation, or as measured by 24-hour urine collection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify